Obtain Real World Insights of Acquired Hemophilia A Patients in Japan2 - ORIHIME2 study

Chugai Pharmaceutical Co., Ltd.0 个研究点目标入组 200 人开始时间: 2022年3月17日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•Patients for whom any of the following criteria apply will be excluded from this study. The entire observation period will apply for all criteria. 1)Patients assigned the receipt disease name, [antiphospholipid syndrome] (confirmed) 2)Patients assigned the receipt disease name, [lupus anticoagulant] (confirmed) 3)Patients assigned the receipt disease name, [acquired coagulation factor XIII deficiency] (confirmed) 4)Patients assigned the receipt disease name, [autoimmune acquired Von Willebrand's disease] (confirmed) 5)Patients assigned the receipt disease name, [acquired factor V deficiency] (confirmed) 6) Patients assigned the receipt idisease name [primary antiphospholipid antibody syndrome] (confirmed)

发起方